Reliable Brokers
Online Investing
Alerts & Analysis
Easy Trading

Galera Therapeutics (NASDAQ: GRTX) implodes 80% on FDA decision against company

Hey, the FDA is the decision maker here, what they say goes

Update : 10 Aug 2023, 04:50 PM

Galera Therapeutics (NASDAQ: GRTX) stock implied 80% and change. GRTX stock plunged because the Food and Drug Administration, the FDA, refused authorisation for the company’s treatment for radiation caused mouth ulcers in cancer patients. There is a speculative opportunity here as a result. But it is indeed highly, highly speculative and is something that most won’t even want to consider.

The FDA’s decision: “Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s New Drug Application (NDA) for avasopasem manganese (avasopasem) for radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer undergoing standard-of-care treatment. In the CRL, the FDA communicated that the results from the Phase 3 ROMAN trial together with the supporting data from the GT-201 trial are not sufficiently persuasive to establish substantial evidence of avasopasem’s effectiveness and safety for reducing severe oral mucositis in patients with head and neck cancer. FDA stated that results from an additional clinical trial will be required for resubmission.”

Galera Therapeutics stock price from Google Finance

This is not, though, the end. It is possible to contest such findings. Firstly, to simply ask for a review, a reconsideration. Then to argue the case in favour of the drug and or treatment. Finally, there’s always the option of doing another trial to gain that proof desired. 

Galera is reducing headcount: “By Denny Jacob Galera Therapeutics will reduce its workforce by 70% as part of a broader restructuring to extend its cash runway” as it first goes through the early stages of that process and mulls over what to do in the longer term.

A reasonable expectation is that there will be no large scale stock issue anytime soon - that would be horribly dilutive given this news and the stock price movement in response. 

But that then gives that speculative opportunity. It’s very much a long shot but it has worked some times. Getting the FDA to reconsider that refusal and see what then happens. Ourselves we’d suggest looking elsewhere for speculative opportunities for the risk reward ratio here looks high. But given that risk appetite does vary it might still be of interest to some. Galera’s not dead and gone but it’s definitely wounded.

Top Brokers